Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


India Rolls Out Modicare - Can It Redefine Healthcare Access, Market Potential?

Executive Summary

India has rolled out its massive government-funded health care program, expanding access to treatment to more than 100 million families. Though ambitious and complex and a scheme that could face intense scrutiny in the run up to general elections next year, the sheer scale of the initiative may also throw up significant market expansion or partnering opportunities for hospitals and pharma.

You may also be interested in...

India Budget Focuses On Huge Health Insurance Scheme Ahead Of Elections

India’s government has hiked healthcare spending in its new budget by 13.5% ahead of national elections, earmarking the lion’s share for its flagship new health insurance scheme for the nation’s poorest half-billion people. But outlays for the stretched core public health-delivery system have stagnated.

Novartis Pharma CEO On Star Products, Pricing And Rebates

Paul Hudson, CEO, Novartis Pharmaceuticals, was recently in India along with the executive leadership team of the Swiss multinational. In a wide-ranging exclusive interview with Scrip, he discussed Cosentyx’s edge over its competition, Entresto’s “incredibly bright future”, including in emerging markets like India, and why transparency on the scale of rebates in the US is "overdue."

Roche India Mandate 'Completely Different' Says New Head Bezzera

Lara Bezerra, Roche’s new managing director in India, outlines in an interview with Scrip how the Swiss multinational is now looking at the Indian market through a different lens and beyond short-term gains.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts